Total Payments
$6,673
2024 Payments
$646.90
Companies
39
Transactions
437
Medicare Patients
14,274
Medicare Billing
$728,753
Payment Breakdown by Category
Food & Beverage$6,656 (99.7%)
Education$17.23 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,656 | 434 | 99.7% |
| Education | $17.23 | 3 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,610 | 101 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $783.73 | 101 | $0 (2022) |
| Amgen Inc. | $368.47 | 23 | $0 (2024) |
| Novo Nordisk Inc | $365.70 | 21 | $0 (2024) |
| Astellas Pharma US Inc | $357.15 | 19 | $0 (2023) |
| Esperion Therapeutics, Inc. | $317.71 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $264.47 | 16 | $0 (2024) |
| Edwards Lifesciences Corporation | $255.51 | 3 | $0 (2020) |
| Amarin Pharma Inc. | $235.84 | 13 | $0 (2023) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $221.59 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $646.90 | 41 | Novartis Pharmaceuticals Corporation ($215.56) |
| 2023 | $837.81 | 39 | Novartis Pharmaceuticals Corporation ($292.85) |
| 2022 | $1,037 | 70 | Novartis Pharmaceuticals Corporation ($245.94) |
| 2021 | $1,352 | 100 | Novartis Pharmaceuticals Corporation ($351.53) |
| 2020 | $366.54 | 21 | Amgen Inc. ($67.98) |
| 2019 | $793.58 | 61 | HeartFlow, Inc. ($148.65) |
| 2018 | $824.49 | 51 | Novartis Pharmaceuticals Corporation ($106.50) |
| 2017 | $814.73 | 54 | Novartis Pharmaceuticals Corporation ($211.52) |
All Payment Transactions
437 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $8.26 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $2.19 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $5.39 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/13/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $1.53 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $2.63 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/09/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $1.40 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/09/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $1.19 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/08/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $1.07 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $6.21 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/07/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $6.94 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: DIABETES | ||||||
| 07/10/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/23/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $6.77 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $0.77 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 06/04/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Not Applicable | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 3,463 | 6,215 | $530,577 | $170,124 |
| 2022 | 17 | 3,495 | 4,906 | $479,708 | $184,054 |
| 2021 | 20 | 3,603 | 5,319 | $461,035 | $198,988 |
| 2020 | 17 | 3,713 | 5,665 | $450,041 | $175,588 |
Total Patients
14,274
Total Services
22,105
Medicare Billing
$728,753
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,141 | 1,496 | $356,377 | $129,021 | 36.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 970 | 1,195 | $61,411 | $11,852 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 65 | 65 | $20,119 | $6,828 | 33.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 503 | 693 | $11,781 | $5,813 | 49.3% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 285 | 595 | $24,347 | $4,944 | 20.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 38 | 38 | $13,385 | $3,706 | 27.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 38 | 39 | $8,279 | $2,337 | 28.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 17 | $3,165 | $1,030 | 32.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 122 | 137 | $4,110 | $831.47 | 20.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $2,021 | $757.35 | 37.5% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 43 | 44 | $4,312 | $754.74 | 17.5% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 42 | 42 | $4,116 | $736.77 | 17.9% |
| 85610 | Blood test, clotting time | Office | 2023 | 98 | 168 | $4,324 | $698.92 | 16.2% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 37 | 38 | $3,648 | $314.01 | 8.6% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 36 | 36 | $3,456 | $307.32 | 8.9% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 16 | 1,600 | $5,724 | $192.31 | 3.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 1,133 | 1,620 | $307,941 | $140,270 | 45.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 952 | 1,246 | $62,788 | $12,331 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $15,666 | $6,241 | 39.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 56 | 72 | $12,812 | $5,652 | 44.1% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2022 | 325 | 636 | $22,692 | $4,706 | 20.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 43 | 43 | $10,820 | $4,332 | 40.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 64 | 66 | $9,207 | $3,821 | 41.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 515 | 731 | $12,427 | $2,163 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 13 | $2,619 | $1,022 | 39.0% |
About Dr. Samuel Woolbert, MD
Dr. Samuel Woolbert, MD is a Cardiovascular Disease healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1154318681.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Woolbert, MD has received a total of $6,673 in payments from pharmaceutical and medical device companies, with $646.90 received in 2024. These payments were reported across 437 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($6,656).
As a Medicare-enrolled provider, Woolbert has provided services to 14,274 Medicare beneficiaries, totaling 22,105 services with total Medicare billing of $728,753. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Plano, TX
- Active Since 09/30/2005
- Last Updated 06/13/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1154318681
Products in Payments
- ENTRESTO (Drug) $1,252
- XARELTO (Drug) $803.51
- LEQVIO (Drug) $357.88
- VERQUVO (Drug) $264.47
- Vascepa (Drug) $235.84
- Repatha (Biological) $232.07
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $224.46
- LifeVest (Device) $221.59
- LEXISCAN (Drug) $214.78
- NEXLETOL (Drug) $192.71
- Rybelsus (Drug) $177.65
- Ozempic (Drug) $176.54
- PRALUENT (Drug) $162.28
- JARDIANCE (Drug) $156.26
- Lexiscan (Drug) $142.37
- Corlanor (Drug) $136.40
- (6342) Intrasight Integrated (Device) $133.93
- NEXLIZET (Drug) $125.00
- WATCHMAN (Device) $97.08
- PRALUENT ALIROCUMAB INJECTION (Biological) $88.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Plano
Srinivasa Potluri, Md, MD
Cardiovascular Disease — Payments: $783,265
Cardiovascular Disease $783,265
Dr. David Brown, M.d, M.D
Cardiovascular Disease — Payments: $256,750
Cardiovascular Disease $256,750
David Rawitscher, Md, MD
Cardiovascular Disease — Payments: $244,805
Cardiovascular Disease $244,805
Sahil Bakshi, Do, DO
Cardiovascular Disease — Payments: $193,440
Cardiovascular Disease $193,440
Mordecai Klein, Md, MD
Cardiovascular Disease — Payments: $162,433
Cardiovascular Disease $162,433
Dr. Vijay Ramanath, M.d, M.D
Cardiovascular Disease — Payments: $123,142
Cardiovascular Disease $123,142